1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Actemra/ RoActemra (tocilizumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Actemra/ RoActemra (tocilizumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Actemra (tocilizumab) is a first-in-class, recombinant, humanized, IgG1 mAb against the interleukin-6 receptor (IL-6R), and is indicated for the treatment of RA patients with moderate to severe, active disease. It was developed by Genentech (now a wholly-owned subsidiary of Roche). Tocilizumab is marketed under the brand name Actemra in the US, and as RoActemra in the 5EU by Roche. Chugai has the development and marketing rights to the product in Japan.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Actemra/RoActemra including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Actemra/RoActemra for the top 10 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Actemra/RoActemra performance.
- Obtain sales forecast for Actemra/RoActemra from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Table Of Contents

Actemra/ RoActemra (tocilizumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Diagnosis 20
4.1.2 Treatment Guidelines 22
4.1.3 Leading Prescribed Drugs for the Treatment of RA 31
4.1.4 Clinical Practice 32
5 Competitive Assessment 37
5.1 Overview 37
6 Actemra/RoActemra (tocilizumab) 39
6.1 Overview 39
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 44
6.5 Forecast 45
7 Appendix 46
7.1 Bibliography 46
7.2 Abbreviations 50
7.3 Methodology 53
7.4 Forecasting Methodology 53
7.4.1 Diagnosed RA Patients 53
7.4.2 Percentage of Drug-Treated Patients 54
7.4.3 General Pricing Assumptions 54
7.4.4 Individual Drug Assumptions 56
7.4.5 Generic and Biosimilar Erosion 57
7.5 Primary Research - KOLs Interviewed for This Report 58
7.6 Primary Research - Prescriber Survey 60
7.7 About the Authors 61
7.7.1 Analyst 61
7.7.2 Reviewer 61
7.7.3 Therapy Area Director 62
7.7.4 Global Head of Healthcare 62
7.8 About GlobalData 63
7.9 Disclaimer 63

1.1 List of Tables

Table 1: Symptoms of RA 18
Table 2: 1987 ACR Diagnostic Criteria for RA 21
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 22
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 24
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 27
Table 6: EULAR 2013 Criteria for RA Remission 28
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 32
Table 8: Leading Branded Treatments for RA 2014 38
Table 9: Product Profile - Actemra 42
Table 10: Actemra SWOT Analysis, 2014 44
Table 11: Global Sales Forecasts ($m) for Actemra, 2013-2023 45
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 60

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 17
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 28
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 29
Figure 5: Flowchart for the Management of RA - EULAR 2013 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze the challenges and opportunities of developing breakthrough therapies, compare difference fast track drug development approaches and the potential risk and rewards of gaining ...

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Alpha Mannosidosis Market: Overview With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in China

  • March 2017
    4 pages
  • Opioid  

  • China  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Opioid Market in the US

  • March 2017
    24 pages
  • Opioid  

    Mortality  

  • United States  

    North America  

View report >

Therapy Market

2 days ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.